Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - lakosamiid - epilepsia - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ucb pharma s.a. - lakosamiid - epilepsiad, osaline - antiepileptics, - lacosamide ucb on näidustatud monotherapy ja adjunctive ravi ravi osaline algusega krambid koos või ilma sekundaarse teha üldistusi täiskasvanud, noorukid ja lapsed alates 4-aastastel epilepsia.

Euroopa Liit - eesti - EMA (European Medicines Agency)

extrovis eu ltd. - lakosamiid - epilepsia - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

laboratoires delbert - histamiini dihüdrokloriid - leukeemia, müeloidne, äge - immunostimulants, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). ceplene efektiivsus ei ole täielikult tõestatud üle 60-aastastel patsientidel.

Eesti - eesti - Ravimiamet

dr. gerhard mann chem.-pharm. fabrik gmbh - timolool+dorsolamiid - silmatilgad, lahus - 5mg+20mg 1ml 5ml 6tk; 5mg+20mg 1ml 5ml 3tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - timolool+dorsolamiid - silmatilgad, lahus - 5mg+20mg 1ml 5ml 3tk

Eesti - eesti - Ravimiamet

santen oy - timolool+dorsolamiid - silmatilgad, lahus - 5mg+20mg 1ml 10ml 1tk; 5mg+20mg 1ml 10ml 3tk; 5mg+20mg 1ml 10ml 2tk

Eesti - eesti - Ravimiamet

santen oy - timolool+dorsolamiid - silmatilgad, lahus - 5mg+20mg 1ml 5ml 3tk; 5mg+20mg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

bausch + lomb ireland limited - timolool+dorsolamiid - silmatilgad, lahus - 5mg+20mg 1ml 5ml 1tk; 5mg+20mg 1ml 5ml 4tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - brinsolamiidi, brimonidine tartraat - ocular hypertension; glaucoma, open-angle - oftalmoloogilised vahendid - kõrge silmasisese rõhu (iop) vähenemine avatud nurga glaukoomi või okulaarse hüpertensiooniga täiskasvanud patsientidel, kellel monoteraapia annab iop-i vähesuse.